RIPK3 and breast cancer: Next, we treated YARS-overexpressing breast cancer cells with necroptosis inhibitors, including Nec-1 (inhibitor of RIPK), GSK’872 (inhibitor of RIPK3), and NSA (inhibitor of MLKL kinase), after SM/z-VAD.fmk treatment to confirm whether SM promotes necroptosis compared to apoptosis.